The FDA has approved obecabtagene autoleucel for adults with relapsed refractory B-cell precursor acute lymphoblastic leukemia. The approval was based on a study that showed a 42% complete remission rate within 3 months of infusion. Common adverse events included cytokine release syndrome, neurologic toxicities, infections, and musculoskeletal pain. Obecabtagene autoleucel is administered as a split dose infusion on Day 1 and Day 10 after lymphodepleting chemotherapy. The total recommended dose is 410 X 10^6 CD19 chimeric antigen receptor-positive viable T-cells. This treatment provides a new option for patients with relapsed or refractory acute lymphoblastic leukemia.
Source link
FDA approves obecabtagene autoleucel for adult leukemia treatment
